Open Orphan ink contract with Japanese firm Carna Bioscience
Specialising in kinase biology and innovative treatments against cancer and immune disorders, Japanese-based Carna Bioscience will be in partnership with Open Orphan’s Venn Life Sciences.
Venn will provide Carna with expertise ranging from chemistry manufacturing to clinical trial management as well as biometry, legal and regulatory support.
Cathal Friel, Chief Executive of Open Orphan said the contract was “an exciting one,” commenting:
“We are now providing a much broader range of pharmaceutical services and the Venn team have managed to transition the provision of its initial pre-clinical consultancy services to Carna into a formal Phase 1 Clinical Trial.”
Building on several years of collaboration between Venn and Carna, the contract is further evidence of Open Orphan’s strategy to secure long-term partnership contracts to deliver recurring revenues for the business.
"This contract is further evidence of delivering against one of Open Orphan's key objectives, transforming Venn,” added Mr Friel.
“We look forward to delivering the contract for Carna Bioscience and I look forward to announcing more positive news in due course."Follow News & Updates from Open Orphan:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.